ClinicalTrials.gg
Not yet recruitingNCT06614608ASKC200Updated Sep 27, 2024

The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain

A Phase 1 interventional study of 5% ASKC200 and 1% ASKC200 in Osteoarthritis, Knee and Pain, sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-27.

Sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd. (part of Beijing Aosaikang Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.

Planned enrollment
102nd of 115
24 · median 100
Started
2024
with 12 others
Phase 1
10 of 136
6 open now
Primary completion
2025-04
later than 6 of 31 live
Registered
108th of 136
by date

Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 102nd largest by planned enrollment of the 115 interventional ones that give a count, is one of 13 that started in 2024, is one of 10 in phase 1, reaches primary completion later than 6 of the 31 other live ones, and was the 108th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Osteoarthritis, Knee with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKC200 in subjects with OA of the knees and determine the phase II recommended dose. Assigned doses will be applied for 60 minutes on each of four consecutive days.

Read the detailed description

Subjects will be randomized to one of the two Arms in this study: 5% ASKC200 or 1% ASKC200. All subjects will receive 4 consecutive days of treatment and will then be followed up until the Day 34 visit.

The NRS score of weekly average of average daily pain intensity (WAADPI) of the study knee should ≥ 5 and the NRS score of WAADPI of the contralateral knee should \< 4 at screening.

Data will be collected from Day 1 through Day 5 and then again on Days 19 and 34 for efficacy, tolerability, and safety measures.

03

Conditions studied

  • Osteoarthritis, Knee
  • Pain
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign prior to any inspection and evaluation, and understand and follow test requirements;
  2. Age 40-75 years old (including boundary value) at the time of signing the informed consent, gender is not limited;
  3. Primary knee osteoarthritis was confirmed by clinical and imaging examination;
  4. Knee osteoarthritis pain history ≥6 months;
  5. Tibial joint X-ray within 3 months prior to drug administration showed that the tibiofemoral joint of the target knee was graded Kellgren-Lawrence II or III;
  6. Before the first medication, the WAADPI NRS score of the study knee was ≥5, and the WAADPI NRS score of the contralateral knee was \<4;
  7. Be willing to discontinue the use of nonsteroidal anti-inflammatory drugs, acetaminophen, and other pain medications, and only use the acetaminophen provided in the study for emergency treatment of knee osteoarthritis pain during the study period;
  8. (BMI) ≤40.0 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. Secondary arthritis caused by other causes;
  2. The study knee has other knee pathologic findings confirmed by clinical evaluation or imaging
  3. There are other conditions that can cause study knee pain or other physical pain;
  4. Other medications for osteoarthritis were used within 1 week prior to the first dose;
  5. Patients with chronic pain in other parts of the body requiring long-term oral analgesic therapy, or those requiring combined treatment with systemic ;
  6. Open knee injury or knee surgery occurred in the study knee within 6 months before the first medication; Or have had any major surgical procedures within 3 months prior to the first medication;
  7. The study knee has received intra-articular injection treatment (such as steroids or sodium hyaluronate, etc.) within 3 months before the first medication;
  8. Received physical therapy for study knee osteoarthritis (such as electrotherapy or acupuncture) within 3 months before the first medication;
  9. Used any capsaicin-containing product or non-steroidal anti-inflammatory drug on the knee within 2 weeks prior to the first administration;
  10. Have An open wound, skin erythema or edema, skin infection, or any other skin lesion in the study knee prior to initial administration;
  11. A history of alcohol or drug dependence within 12 months prior to the first administration or a positive urine drug test during the screening period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    5% ASKC200

    A single dose will be topically applied to study knees for 60 minutes on Visit 1 on Day 1, Day 2, Day 3, and Day 4.

    Drug: 5% ASKC200

  • Experimental
    1% ASKC200

    A single dose will be topically applied to study knees for 60 minutes on Visit 1 on Day 1, Day 2, Day 3, and Day 4.

    Drug: 1% ASKC200

Interventions

  • Drug5% ASKC200

    5% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.

  • Drug1% ASKC200

    1% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of1% for this study.

06

What researchers measure

Primary outcomes

  1. Safety:Incidence of adverse events(AEs)

    All adverse medical events occurring after the subject receives the investigational drug, which may be manifested as symptoms, signs, diseases, or abnormalities in laboratory tests, but may not necessarily have a causal relationship with the investigational drug.

    Time frame: 34 days

Secondary outcomes

  1. Efficacy:Change in the NRS score of weekly average of average daily pain intensity(WAADPI) From Baseline

    The average amount of pain as reported by the subject using a 0 - 10 numerical rating scale (NRS). Higher scores indicate more pain.

    Time frame: Day 19, Day 34

  2. Efficacy:Remission ratio of study knee according to NRS score

    The average amount of pain as reported by the subject using a 0 - 10 numerical rating scale (NRS). Higher scores indicate more pain.

    Time frame: Day 19, Day 34

  3. Efficacy:Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score From Baseline

    The WOMAC Index is a questionnaire used to assess health status and health outcomes in KOA. The questionnaire contains 24 questions(0-10) on pain, stiffness and physiology, will ask participants to complete the WOMAC questionnaire considering their symptoms in the past 48 hours.Higher scores indicate more pain.

    Time frame: Day 19, Day 34

  4. Efficacy:Change in patients clinical general impression (PCGI-C)

    The change in patients clinical general impression as reported by the subject using a 0 - 7 scale (PCGI-C).Higher scores indicate worse state of pain.

    Time frame: Day 19, Day 34

  5. Efficacy:The use of acetaminophen

    Subjects will record their administration of acetaminophen . The number of days the subjects use acetaminophen and the proportion of subjects who use acetaminophen will be counted.

    Time frame: 34 days

  6. Maximum Observed Plasma Concentration (Cmax) for ASKC200

    Time frame: Day1-Day5

  7. Time of First Occurrence of Cmax (Tmax) for ASKC200

    Time frame: Day1-Day5

  8. Area Under the Plasma Concentration-time Curve from Time 0 to 24 Hours (AUC24) for for ASKC200

    Time frame: Day1-Day5

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Apr 2025, 6 months later.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's planned 6 months is below that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2024
First posted
Sep 26, 2024
StartEst.
Oct 2024
Primary completionEst.
Apr 2025
CompletionEst.
Dec 2025
Last update
Sep 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06614608
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Oct 2024 (estimated)
Primary completion
Apr 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Sep 27, 2024

Study contacts

Kexin Li
Contact
Kexinli6202@163.com
+86 10 85133642

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion